Skip to content

Vehicle (placebo)

DRUG16 trials

Sponsors

Zalicus, Bausch & Lomb Incorporated, Medicis Global Service Corporation, Botanix Pharmaceuticals, Pfizer

Conditions

Atopic DermatitisAtopic Dermatitis (AD)Bacterial ConjunctivitisCorneal Endothelial DystrophyCorneal Epithelial DefectDiabetic Foot Ulcer (DFU)Dystrophic Epidermolysis BullosaEndothelial Dysfunction

Phase 1

Phase 2

Study of CRx-191 to Assess Activity in Plaque Psoriasis
CompletedNCT00557739
ZalicusPlaque Psoriasis
Start: 2007-11-30End: 2008-01-31Target: 20Updated: 2008-09-25
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
CompletedNCT00972777
Bausch & Lomb IncorporatedBacterial Conjunctivitis
Start: 2009-10-31End: 2011-02-28Updated: 2012-03-29
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
CompletedNCT01703793
Medicis Global Service CorporationSeborrheic Dermatitis
Start: 2012-09-30End: 2013-01-31Updated: 2013-01-09
A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
CompletedNCT03024255
Botanix PharmaceuticalsHyperhidrosis
Start: 2016-12-22End: 2017-09-19Updated: 2023-05-16
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
CompletedNCT03850483
PfizerPsoriasis
Start: 2019-04-08End: 2021-04-20Updated: 2022-06-29
Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
CompletedNCT03903822
PfizerAtopic Dermatitis
Start: 2019-05-13End: 2020-05-07Updated: 2021-03-29
A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
CompletedNCT06058000
Qilu Pharmaceutical Co., Ltd.Atopic Dermatitis
Start: 2023-11-13End: 2024-09-30Updated: 2025-03-12
A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
RecruitingNCT06594393
Xinnate ABDystrophic Epidermolysis Bullosa, Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa
Start: 2026-01-30End: 2027-06-30Target: 32Updated: 2026-01-29
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
CompletedNCT06810050
CAGE Bio Inc.Atopic Dermatitis (AD)
Start: 2024-12-18End: 2025-10-30Updated: 2026-04-02
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Not yet recruitingNCT07005180
Hillhurst Biopharmaceuticals, Inc.Parkinson Disease
Start: 2026-02-28End: 2027-03-31Target: 36Updated: 2026-01-08
To Evaluate the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects Caused by Neurotrophic Keratitis
CompletedNCT07120308
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Corneal Epithelial Defect
Start: 2021-09-15End: 2023-01-30Updated: 2025-08-13

Unknown Phase

Related Papers